Government ContextGovernment Context
TopicsAgenciesOrganizationsDocumentsPricingLog inCreate account
TopicsAgenciesOrganizationsDocumentsPricing
LoginCreate account
DetailsRelated

Tab 21 - Onsolis Clinical Pharmacology Review Excerpt

Supporting & Related MaterialFDA-2026-P-4762-0023
Document

Details

The document's own metadata, straight from the source system.

Title
Tab 21 - Onsolis Clinical Pharmacology Review Excerpt
Posted
May 1, 2026
Agency
Food and Drug Administration (FDA)
Topics
  • Mental Health & Substance Abuse
  • Pharmaceutical Policy
View on regulations.gov ↗
Related

Related documents

Other documents filed with this rulemaking.

View related documents
Supporting & Related Material
Tab 18 - Belbuca REMS
No comment periodMay 1, 2026
Supporting & Related Material
Tab 26 - Belbuca Clinical Pharmacology and Biopharmaceutics Review Excerpt
No comment periodMay 1, 2026
Supporting & Related Material
Tab 19 - FDA Draft Guidance on Buprenorphine Hydrochloride Buccal 2025
No comment periodMay 1, 2026
Supporting & Related Material
Tab 14 - Belbuca PI
No comment periodMay 1, 2026
Supporting & Related Material
Tab 27 - FDA Guidance on IR SUPAC
No comment periodMay 1, 2026
Supporting & Related Material
Tab 20 - Suboxone Clinical Pharmacology Review Excerpt
No comment periodMay 1, 2026
Supporting & Related Material
Tab 15 - Chemo Joint Letter 2026 Public Version
No comment periodMay 1, 2026
Supporting & Related Material
Tab 31 - Olechno et al 2026 Excerpt
No comment periodMay 1, 2026

On this page

DetailsRelated
Government ContextGovernment Context

Track federal rulemaking documents, topics, and agencies — built on primary sources across the federal government.

ExploreDocumentsTopicsAgenciesOrganizations
CompanyAboutData sourcesPricing
LegalPrivacyTerms
© 2026 Government Context. Built on primary government sources.Not affiliated with any U.S. government agency.